<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">3199</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url">http://dx.doi.org/10.31782/IJCRR.2020.122406</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>Rational Development of Carbamazepine Osmotic-Controlled Release Oral Delivery System for Multiple Therapeutic Advantages&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gatlewar</surname><given-names>Shrinivas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Meshram</surname><given-names>Rutuja</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gangane</surname><given-names>Purushottam S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mahapatra</surname><given-names>Debarshi Kar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mahajan</surname><given-names>Nilesh M.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>14</day><month>12</month><year>2020</year></pub-date><volume>4)</volume><issue/><fpage>43</fpage><lpage>48</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Background: Carbamazepine is used in the management of seizures by decreasing the central nervous system disorganized electrical activity and also has analgesic properties. It exerts serious side effects in normal administration owing to the extrapyramidal effect which signifies the importance of its incorporation into the extended-release system to reduce the possible side-effects associated with the drug.&#13;
Objective: In the present study, multiple extended-release systems of Carbamazepine was formulated using various polymers. The effect of viscosity modifying polymers of different grades and its contribution to the release behaviour was examined. Different formulations were prepared and studied for their drug release potentials. Among them, selected formulations were further evaluated for dimensions of the portal.&#13;
Methodology: Trial batches were designed with osmogen and cellulose polymers along with solubility enhancer as the model drug used to have low solubility. The optimization of the formulation was done by wavering concentration of cellulose polymers and the dimensions of the release portal were determined.&#13;
Result: A new strategy for extended delivery has been accomplished by extended-release solid oral tablet formed by the combination of solubility enhancers and cellulose polymers. The arrangement of a hydrophilic polymer with a surfactant as solubility promoter and the use of cellulose polymer represents an innovative and effective approach for the delivery of poorly water-soluble. The study further can be used to deliver a cost-effective and robust system for water-insoluble drugs in a zero-order manner.&#13;
Conclusion: The rapid development of these investigational therapeutic formulations will put forward new avenues for future commercialization of drug after completion of required clinical studies.&#13;
</p></abstract><kwd-group><kwd>Carbamazepine</kwd><kwd> Osmotic</kwd><kwd> Controlled Release</kwd><kwd> Oral Delivery System</kwd><kwd> Drug release</kwd><kwd> Solubility</kwd></kwd-group></article-meta></front></article>
